Kyowa Kirin Head Sees Major Global Status For Newly Formed Biotech
This article was originally published in PharmAsia News
Executive Summary
Kyowa Kirin intends to go head to head in 2012 with the world's largest biotechnology companies, the president of the recently formed Japanese company says. Created through a merger of Kyowa Hakko Kogyo and Kirin Pharma last October, the company is banking on its advanced antibody technologies to help it catch up with big biotechs such as Amgen and Genentech of the United States. The key technologies in that effort are Potelligent and Complegent, already licensed to 10 drug makers, including major multinationals. Kyowa Kirin President Yuzuru Matsuda anticipates blockbuster status for drugs derived from the technologies, which would lead to a "rain fall" of royalties for the company. (Click here for more - a subscription may be required
You may also be interested in...
Kyowa Hakko Kirin Licenses Anti-LIGHT MAB To Sanofi-Aventis
TOKYO - Kyowa Hakko Kirin signed a licensing agreement with Sanofi-Aventis for worldwide co-development and marketing rights, excluding Japan and Asia, for Kyowa's anti-LIGHT fully humanized monoclonal antibody, the company said May 14
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.